Flex Pharma Reports First Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- McKesson reports cybersecurity incident affecting its information systems
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- BioNTech ends colorectal cancer mRNA therapy trial early
Flex Pharma (FLKS) PT Lowered to $8 at Jefferies; HotShot Sales Impacted by Seasonality
May 4, 2017 8:19 AM EDTJefferies lowered its price target on Flex Pharma (NASDAQ: FLKS) to $8.00 (from $9.00) while maintaining a Buy rating.
Analyst Matthew Andrews notes HotShot sales were affected by seasonality as expected though there are signals that Q2 is off to a good start.
The firm cut FY 2017 EPS from ($1.90) to ($2.13)
... More